The absence of amplification and mutation overlap in NSCLC has been proposed as an explanation for the observed poor outcomes of classic anti-HER2 agents employed in breast cancer therapeutics [26,27]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.